A Unique Herbal Product for the Symptomatic Treatment of Over Active Bladder

Projektinformationen

SAGAPROPLUS

ID Finanzhilfevereinbarung: 782075

DOI

10.3030/782075

Projekt abgeschlossen

EK-Unterschriftsdatum 9 August 2017

Startdatum 1 August 2017

Enddatum 30 November 2017

Finanziert unter

• SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

SAGAMEDICA - HEILSUJURTIR EHF
Iceland

Periodic Reporting for period 1 - SAGAPROPLUS (A Unique Herbal Product for the Symptomatic Treatment of Over Active Bladder)

Berichtszeitraum: 2017-08-01 bis 2017-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Over active bladder (OAB) is an age-related syndrome, more frequent in adults +65. It is extremely common, affecting ~500 million people and expected to keep rising due to aging of developed societies. OAB represents a human and economical burden for which no good solutions are available. OAB treatment has two lines of intervention: i) changes in lifestyle (diet, Kegel exercises) that are only partially effective and dependent on patients’ commitment, and ii) pharmacological treatment (anticholinergic drugs that inhibit contraction of bladder muscles), only partially effective and associated with multiple side effects, resulting in extremely high drop-out rates.
SagaMedica has identified the need for better treatments for OAB and has developed SagaPro+, a natural solution for dealing with OAB symptoms. SagaPro+ is made from leaves of plant Angelica Archangelica, and offers unique properties for OAB management: i) efficiency: SagaPro+ has been validated in OAB patients who reported an improvement of their symptoms, ii) safety: no side effects have been observed, iii) natural origin: SagaPro+ is 100% natural and consists only of Angelica extracts, and iv) sustainability: its harvesting and manufacturing processes have been kept local, sustainable and eco-friendly.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

We have performed a study to confirm viability of SAGAPRO+: i) technically we designed a large-scale clinical trial and defined the requirements for industrialization, ii) commercially we investigated the regulatory pathway for SagaPro+, as well as carried out a detailed study of OAB market, and iii) financially, we updated our business plan and confirmed project’s profitability.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Economic impact: SagaPro+’s affordable price will alleviate both direct and indirect costs of OAB management to the healthcare system. Societal impact: a natural solution like SagaPro+ will alleviate the symptoms without side effects improving the quality of life of affected patients allowing them to have a normal everyday life.

image-2.png

image-1.png